Adaptive Biotechnologies (
NASDAQ:ADPT)
Dollar Amount of Shares Sold: $242,507,080.65
Number of Insider Stock Sales in the Last 180 Days: 78
Volume of Shares Sold: 4,721,509
Who Sold Shares: Chad M Cohen (CFO), Chad M Robins (CEO), Charles Sang (SVP), Eric Dobmeier (Director), Francis Lo (Insider), Global Investors Lp Viking (Major Shareholder), Harlan S Robins (Insider), Julie Rubinstein (President), Lance Baldo (Insider), Michael J Pellini (Director), Michelle Renee Griffin (Director), Nancy Louise Hill (EVP), Robert Hershberg (Director), Sharon Benzeno (Insider), Stacy L Taylor (SVP) and Susan Bobulsky (SVP)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals.
Read More
